What were Thyrocare Technologies Ltd's latest quarterly results?
Thyrocare Technologies Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +122.7% (stable)
- Revenue Growth YoY: +19.8%
- Operating Margin: 34.0% (volatile)
Thyrocare Technologies Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +32.5%Average6w Streak
In , Thyrocare Technologies Ltd (Diagnostics) is outperforming Nifty 500 with +32.5% relative strength. Fundamentals: Average. On a 6-week streak.
Thyrocare Technologies Ltd Key Facts
- PE Ratio
- 51.2x
- Market Cap
- ₹8,232 Cr
- PAT Growth YoY
- +123%
- Revenue Growth YoY
- +20%
- OPM
- 34.0%
- RS vs Nifty 500
- +32.5%
PE: Mid ExpansionEmerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
💪Debt reduced 51% YoY — balance sheet strengthening
🌐FII stake increased 2.9% this quarter
🏛️DII reducing — stake down 1.3%
💰Trading 12% above estimated fair value
Key Numbers
PAT Growth YoY
+123%
Stable
Revenue YoY
+20%
Stable
Operating Margin
34.0%
+400 bps YoY
PE Ratio
51.2
Current Price
₹517
Dividend Yield
1.80%
Fundamental Score
59/100
Average
3Y PAT CAGR
+37%
Market Cap
8.2K Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Thyrocare Technologies Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +20% | +16% | Stable |
| PAT (Net Profit) | +123% | +37% | Stable |
| OPM | 34.0% | +400 bps | Volatile |
Other Top Diagnostics Stocks Beating Nifty 500
Frequently Asked Questions: Thyrocare Technologies Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Thyrocare Technologies Ltd's profit growing or declining?
Thyrocare Technologies Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +122.7% (latest quarter)
- PAT Growth QoQ: +75.0% (sequential)
- 3-Year PAT CAGR: +36.6%
- Trend: Stable — consistent growth pattern
What is Thyrocare Technologies Ltd's revenue growth trend?
Thyrocare Technologies Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +19.8%
- Revenue Growth QoQ: +14.3% (sequential)
- 3-Year Revenue CAGR: +16.3%
How is Thyrocare Technologies Ltd's operating margin trending?
Thyrocare Technologies Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: +4.0% basis points
- OPM Change QoQ: +4.0% basis points
What is Thyrocare Technologies Ltd's 3-year profit and revenue CAGR?
Thyrocare Technologies Ltd's long-term compounding rates
- 3-Year Profit CAGR: +36.6%
- 3-Year Revenue CAGR: +16.3%
Is Thyrocare Technologies Ltd's growth accelerating or decelerating?
Thyrocare Technologies Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +52.6% bps
- Sequential Acceleration: +91.7% bps
What is Thyrocare Technologies Ltd's trailing twelve month (TTM) performance?
Thyrocare Technologies Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹163 Cr
- TTM PAT Growth: +79.1% YoY
- TTM Revenue: ₹830 Cr
- TTM Revenue Growth: +20.8% YoY
- TTM Operating Margin: 31.9%
Is Thyrocare Technologies Ltd overvalued or undervalued?
Thyrocare Technologies Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 51.2x
- Price-to-Book: 14.1x
What is Thyrocare Technologies Ltd's current PE ratio?
Thyrocare Technologies Ltd's current PE ratio is 51.2x.
- Current PE: 51.2x
- Market Cap: 8.2K Cr
- Dividend Yield: 1.80%
How does Thyrocare Technologies Ltd's valuation compare to its history?
Thyrocare Technologies Ltd's current PE is 51.2x.
- Current PE: 51.2x
- Valuation Assessment: Overvalued
What is Thyrocare Technologies Ltd's price-to-book ratio?
Thyrocare Technologies Ltd's price-to-book ratio is 14.1x.
- Price-to-Book (P/B): 14.1x
- Book Value per Share: ₹37
- Current Price: ₹517
Is Thyrocare Technologies Ltd a fundamentally strong company?
Thyrocare Technologies Ltd is rated Average with a fundamental score of 59.28/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +19.8% (10% weight)
- PAT Growth YoY: +122.7% (10% weight)
- PAT Growth QoQ: +75.0% (10% weight)
- Margins stable (10% weight)
Is Thyrocare Technologies Ltd debt free?
Thyrocare Technologies Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹51 Cr
What is Thyrocare Technologies Ltd's return on equity (ROE) and ROCE?
Thyrocare Technologies Ltd's return ratios over recent years
- FY2024: ROCE 18.0%
- FY2025: ROCE 25.0%
- FY2026: ROCE 35.0%
Is Thyrocare Technologies Ltd's cash flow positive?
Thyrocare Technologies Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹213 Cr
- Free Cash Flow (FCF): ₹190 Cr
- CFO/PAT Ratio: 131% (strong cash conversion)
What is Thyrocare Technologies Ltd's dividend yield?
Thyrocare Technologies Ltd's current dividend yield is 1.80%.
- Dividend Yield: 1.80%
- Current Price: ₹517
Who holds Thyrocare Technologies Ltd shares — promoters, FII, DII?
Thyrocare Technologies Ltd's shareholding pattern (Mar 2026)
- Promoters: 60.9%
- FII (Foreign): 5.4%
- DII (Domestic): 21.0%
- Public: 12.7%
Is promoter holding increasing or decreasing in Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 60.9% (Mar 2026)
- Previous Quarter: 60.9% (Dec 2025)
- Change: -0.01% (decreasing — worth monitoring)
How long has Thyrocare Technologies Ltd been outperforming Nifty 500?
Thyrocare Technologies Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Thyrocare Technologies Ltd a new momentum entry or an established outperformer?
Thyrocare Technologies Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
Is Thyrocare Technologies Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Thyrocare Technologies Ltd may be worth studying
- Earnings growing at +122.7% YoY
- Cash flow is positive — CFO ₹213 Cr
What is the investment thesis for Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +19.8% YoY
Risk Factors (Bear Case)
- Appears overvalued
What is the future outlook for Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.